Indaptus Therapeutics shared its third-quarter results, showing a big drop in research costs and raising about $24 million.

Nov 13, 2026, 4:36 PM ETResultsRead the original at SEC EDGAR

Neutral

The cash and stated ability to fund planned work support operations, but issuing 20.3 million shares reduces existing owners' slice. Research spending fell 82%, and the sleep-device idea remains at early research stage, so the report leaves Indaptus's outlook balanced.

INDP · Indaptus Therapeutics, Inc.

AI read · Neutral

The AI's read

The cash can support planned research and operating costs, and management says it covers expected spending. But existing owners now hold a smaller share of the company. Research spending was 82% lower, after clinical costs and staffing declined. The proposed sleep-device work remains early research, not a proven treatment or a clear source of future sales.

Get alerts for INDP

Follow Indaptus Therapeutics, Inc. (INDP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INDP

Free on the App Store and Google Play, or on the web.